| CAS NO: | 1006036-88-9 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 200mg | 电议 |
| Cas No. | 1006036-88-9 |
| 别名 | 4-[1-[[[2,5-二甲基-4-[[4-(三氟甲基)苯基]甲基]-3-噻吩基]羰基]氨基]环丙基]苯甲酸钠盐 |
| Canonical SMILES | [O-]C(C1=CC=C(C2(NC(C3=C(C)SC(C)=C3CC4=CC=C(C(F)(F)F)C=C4)=O)CC2)C=C1)=O.[Na+] |
| 分子式 | C25H21F3NNaO3S |
| 分子量 | 495.49 |
| 溶解度 | Soluble in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | MK-2894 sodium salt is a highly potent and selective second generation EP4 antagonist.IC50 value:Target: EP4MK-2894 exhibits favorable pharmacokinetic profile in a number of preclinical species and potent anti-inflammatory activity in several animal models of pain/inflammation. MK-2894 also shows favorable GI tolerability profile in rats when compared to traditional NSAID indomethacin. [1]. Blouin M, Han Y, Burch J, Farand J, Mellon C, Gaudreault M, Wrona M, LÉvesque JF, Denis D, Mathieu MC, Stocco R, Vigneault E, Therien A, Clark P, Rowland S, Xu D, O'Neill G, Ducharme Y, Friesen R. The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluorometh |
m.cnreagent.com